Abstract
Patients with cancer are frequently exposed to risk of renal injuries associated with disease-related or iatrogenic causes. Nephrotoxicity is a potential adverse effect of anti-cancer agents and may result in a variety of functional abnormalities, including glomerular or tubular dysfunction, hypertension and disturbance of the renal endocrine function. In this review article, we comprehensively discuss the incidence, clinical presentation, prevention and management of anti-cancer agent-induced renal dysfunction. We focus on both relatively new anti-cancer agents (bevacizumab, gefitinib, gemcitabine, imatinib, rituximab and trastuzumab) and traditional agents (cisplatin, methotrexate, ifosfamide and taxanes) to cover a selection of the most frequently used anti-cancer agents. Increased understanding of the mechanism of renal injury by these agents is considered to be important for developing novel anti-cancer agents that have far fewer adverse effects on kidneys.
Keywords: Acute kidney injury, anti-cancer agents, cisplatin, chemotherapy, electrolyte abnormality, nephrotoxicity.
Anti-Cancer Agents in Medicinal Chemistry
Title:Anti-Cancer Agent-Induced Nephrotoxicity
Volume: 14 Issue: 7
Author(s): Hirotaka Fukasawa, Ryuichi Furuya, Hideo Yasuda, Tatsuo Yamamoto, Akira Hishida and Masatoshi Kitagawa
Affiliation:
Keywords: Acute kidney injury, anti-cancer agents, cisplatin, chemotherapy, electrolyte abnormality, nephrotoxicity.
Abstract: Patients with cancer are frequently exposed to risk of renal injuries associated with disease-related or iatrogenic causes. Nephrotoxicity is a potential adverse effect of anti-cancer agents and may result in a variety of functional abnormalities, including glomerular or tubular dysfunction, hypertension and disturbance of the renal endocrine function. In this review article, we comprehensively discuss the incidence, clinical presentation, prevention and management of anti-cancer agent-induced renal dysfunction. We focus on both relatively new anti-cancer agents (bevacizumab, gefitinib, gemcitabine, imatinib, rituximab and trastuzumab) and traditional agents (cisplatin, methotrexate, ifosfamide and taxanes) to cover a selection of the most frequently used anti-cancer agents. Increased understanding of the mechanism of renal injury by these agents is considered to be important for developing novel anti-cancer agents that have far fewer adverse effects on kidneys.
Export Options
About this article
Cite this article as:
Fukasawa Hirotaka, Furuya Ryuichi, Yasuda Hideo, Yamamoto Tatsuo, Hishida Akira and Kitagawa Masatoshi, Anti-Cancer Agent-Induced Nephrotoxicity, Anti-Cancer Agents in Medicinal Chemistry 2014; 14 (7) . https://dx.doi.org/10.2174/1871520614666140127105809
DOI https://dx.doi.org/10.2174/1871520614666140127105809 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Ideational Fluency in Patients with Rheumatoid Arthritis
Current Rheumatology Reviews β3-Adrenoceptor Control of Lower Genitourinary Tract Organs and Function in Male: An Overview
Current Drug Targets An Arylidene-Thiazolidinedione Derivative, GPU-4, without PPARγ Activation, Reduces Retinal Neovascularization
Current Neurovascular Research Approach to the Patient with Subclinical Cushing’s Syndrome
Current Pharmaceutical Design Bile Acids and Farnesoid X Receptor: Novel Target for the Treatment of Diabetic Cardiomyopathy
Current Protein & Peptide Science Synthesis and Antihypertensive Activity of Novel Quinazolin-4(3H)-one Derivatives
Central Nervous System Agents in Medicinal Chemistry Human Recombinant Leptin Administration as a Potential Obesity Therapy
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Antioxidant Phytochemicals in Pulses and their Relation to Human Health: A Review
Current Pharmaceutical Design Plasma Potassium Levels in Healthy Prehypertension Subjects and the Role of A High Potassium Drink
Current Hypertension Reviews Heat Shock Proteins - Two Sides of a Coin
Current Cardiology Reviews Lipoprotein Subfractions, Uric Acid and Cardiovascular Risk in End-Stage Renal Disease (ESRD) Patients
Current Vascular Pharmacology Uveitis in Rheumatic Diseases
Current Rheumatology Reviews Subject Index Volume 2
Medicinal Chemistry Natural Products as α-Amylase and α-Glucosidase Inhibitors and their Hypoglycaemic Potential in the Treatment of Diabetes: An Update
Mini-Reviews in Medicinal Chemistry Control of Blood Pressure in the Community: An Unsolved Problem
Current Pharmaceutical Design Neonatal Systemic Thrombosis: An Updated Overview
Current Vascular Pharmacology Editorial (Thematic Issue: ‘Lone’ Atrial Fibrillation: No Longer Lone or Even Alone)
Current Pharmaceutical Design Estrogens and Progression of Diabetic Kidney Damage
Current Diabetes Reviews Inflammatory Related Cardiovascular Diseases: From Molecular Mechanisms to Therapeutic Targets
Current Pharmaceutical Design Therapeutic Potential of Probiotics: A Ray of Hope or Nightmare?
Applied Clinical Research, Clinical Trials and Regulatory Affairs